Author

S. T. Pullan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Cell Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 4 Research Focus:differential expression· 3 Research Focus:host-pathogen & immune response· 3 Assay:metagenomics· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

K. Lewandowski· 4 shared M. W. Carroll· 3 shared A. C. Marriott· 2 shared A. S. Walker· 2 shared A. Vaughan· 2 shared B. Hallis· 2 shared D. Foster· 2 shared D. W. Crook· 2 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

K. Lewandowski

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Evaluation of the cross reactivity of neutralising antibody response in vaccinated human and convalescent hamster sera against SARS-CoV-2 variants up to and including JN.1 using an authentic virus neutralisation assay

N. S. Coombes, K. R. Bewley, Y. Le Duff, N. Alami-Rahmouni, K. A. Ryan, S. Kempster, D. Ferguson, E. R. Davies, T. M. Weldon, E. S. Cross, L. Smith, C. Norris, K. R. Rogers-Broadway, K. Lewandowski, S. Treagus, , S. G. P. Funnell

This study evaluates neutralising antibody responses in vaccinated humans and convalescent hamsters against SARS-CoV-2 variants up to JN.1 using an authentic virus neutralisation assay, finding increased resistance to JN.1 in vaccinated individuals and specific neutralisation patterns in hamsters.

bioRxiv · Oct 21, 2023 · PreprintCell Biology

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

D. Bojkova, P. Reus, L. Panosch, M. Bechtel, T. Rothenburger, J. Kandler, A. Pfeiffer, J. U. Wagner, M. Shumliakivska, S. Dimmeler, R. Olmer, U. Martin, F. Vondran, T. Toptan, F. Rothweiler, , J. Cinatl

This study develops a phenotypic screening platform using caspase 3/7 activity to identify antiviral compounds against SARS-CoV-2, including novel candidates and combinations.

bioRxiv · Jul 17, 2022Pharmacology & Toxicology

Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge

K. A. Ryan, K. R. Bewley, S. A. Fotheringham, P. Brown, Y. Hall, A. C. Marriott, J. A. Tree, L. Allen, M. J. Aram, E. Brunt, K. R. Buttigieg, B. E. Cavell, D. P. Carter, R. Cobb, N. S. Coombes, , M Dennis

This study investigates the dose-dependent response of ferrets to SARS-CoV-2 infection, showing protection against re-challenge and mild clinical disease.

Nature Communications · Jan 4, 2021Peer-reviewedMicrobiology

Succession of physiological stages hallmarks the transcriptomic response of fungus Aspergillus niger to lignocellulose

J. M. van Munster, P. Daly, M. J. Blythe, R. Ibbett, M. Kokolski, S. Gaddipati, E. Lindquist, V. R. Singan, K. W. Barry, A. M. Lipzen, C. Y. Ngan, C. J. Petzold, L. J. G. Chan, M. Arvas, R. Raulo, , D. B. Archer

This study identifies physiological stages in Aspergillus niger's transcriptomic response to lignocellulose substrates, showing conserved metabolic patterns and substrate-specific adaptations.

bioRxiv · Oct 17, 2019Microbiology

Metagenomic Nanopore sequencing of influenza virus direct from clinical respiratory samples

K. Lewandowski, Y. Xu, S. T. Pullan, D. Foster, N. D. Sanderson, A. Vaughan, M. Morgan, N. Bright, J. Kavanagh, R. T. Vipond, M. W. Carroll, A. C. Marriott, K. E. Gooch, M. Andersson, K. Jeffery, , P. C. Matthews

This study uses metagenomic Nanopore sequencing to detect influenza virus in clinical respiratory samples, achieving high sensitivity and complete genome sequencing.

bioRxiv · Jun 19, 2019Microbiology

Nanopore metagenomic sequencing of full length human metapneumovirus (HMPV) within a unique sub-lineage

Y. Xu, K. Lewandowski, S. Lumley, N. D. Sanderson, A. Vaughan, R. T. Vipond, M. W. Carroll, K. Jeffery, D. Foster, A. S. Walker, T. E. A. Peto, D. W. Crook, S. T. Pullan, P. C. Matthews

This study uses Nanopore metagenomic sequencing to directly sequence the full-length HMPV genome from a UK patient, identifying a unique genetic group and demonstrating the utility of Nanopore for clinical diagnosis.

bioRxiv · Dec 17, 2018 · PreprintMicrobiology

Assessment of Metagenomic MinION and Illumina sequencing as an approach for the recovery of whole genome sequences of chikungunya and dengue viruses directly from clinical samples.

L. E. Kafetzopoulou, K. Efthymiadis, K. Lewandowski, A. Crook, D. Carter, J. Osborne, E. Aarons, R. Hewson, J. A. Hiscox, M. W. Carroll, R. Vipond, S. T. Pullan

This study assesses metagenomic sequencing using MinION and Illumina to recover whole genomes of chikungunya and dengue viruses from clinical samples, showing high feasibility for phylogenetic analysis.

bioRxiv · Jun 25, 2018Microbiology